Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Clinical trial NCT02858921 · UNKNOWN
Trial details
- NCT number
- NCT02858921
- Sponsor
- Melanoma Institute Australia
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-08
- Primary completion
- 2022-01-02
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.